

Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/121624/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Alotaibi, Mohammad Hayal, Mohamed, Hanan A., Abdel-Wahab, Bakr F., Hegazy, Amany S., Kariuki, Benson M. ORCID: <https://orcid.org/0000-0002-8658-3897> and El-Hiti, Gamal A. 2019. Crystal structure of 5-(5-(4-chlorophenyl)-1-phenyl-1H-pyrazol-3-yl)-N-phenyl-2-amine, C₂₃H₁₆ClN₅O. Zeitschrift für Kristallographie - New Crystal Structures 234 (3) , 543. 10.1515/ncrs-2018-0546 file

Publishers page: <http://dx.doi.org/10.1515/ncrs-2018-0546>
<<http://dx.doi.org/10.1515/ncrs-2018-0546>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies.


See

<http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Mohammad Hayal Alotaibi*, Hanan A. Mohamed, Bakr F. Abdel-Wahab, Amany S. Hegazy, Benson M. Kariuki and Gamal A. El-Hiti*

Crystal structure of 5-(5-(4-chlorophenyl)-1-phenyl-1*H*-pyrazol-3-yl)-*N*-phenyl-2-amine, $C_{23}H_{16}ClN_5O$



<https://doi.org/10.1515/ncrs-2018-0546>

Received December 1, 2018; accepted February 9, 2019; available online March 4, 2019

Abstract

$C_{23}H_{16}ClN_5O$, monoclinic, $P2_1/c$ (no. 14), $a = 10.0503(6)$ Å, $b = 17.5265(9)$ Å, $c = 22.8763(16)$ Å, $\beta = 91.554(6)^\circ$,

$V = 4028.1(4)$ Å³, $Z = 8$, $R_{gt}(F) = 0.0748$, $wR_{ref}(F^2) = 0.2274$, $T = 296(2)$ K.

CCDC no.: 1896315

Table 1: Data collection and handling.

Crystal:	Colourless needle
Size:	$0.58 \times 0.07 \times 0.02$ mm
Wavelength:	Mo $K\alpha$ radiation (0.71073 Å)
μ :	0.22 mm ⁻¹
Diffractometer, scan mode:	SuperNova, ω
θ_{max} , completeness:	29.9°, >99%
$N(hkl)_{measured}$, $N(hkl)_{unique}$, R_{int} :	41529, 10169, 0.077
Criterion for I_{obs} , $N(hkl)_{gt}$:	$I_{obs} > 2 \sigma(I_{obs})$, 4311
$N(param)_{refined}$:	541
Programs:	CrysAlis ^{PRO} [1], SHELX [2, 3], WinGX/ORTEP [4]

*Corresponding authors: **Mohammad Hayal Alotaibi**, National Center for Petrochemicals Technology, King Abdulaziz City for Science and Technology, P.O. Box 6086, Riyadh 11442, Saudi Arabia, e-mail: mhhalaotaibi@kacst.edu.sa; and **Gamal A. El-Hiti**, Department of Optometry, College of Applied Medical Sciences, King Saud University, P.O. Box 10219, Riyadh 11433, Saudi Arabia, e-mail: gelhiti@ksu.edu.sa

Hanan A. Mohamed and Bakr F. Abdel-Wahab: Department of Chemistry, College of Science and Humanities, Shaqra University, Duwadimi, Saudi Arabia; and Applied Organic Chemistry Department, National Research Centre, Dokki, Giza, Egypt

Amany S. Hegazy and Benson M. Kariuki: School of Chemistry, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, UK

The asymmetric unit of the title crystal structure containing two molecules is shown in the figure. Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.

Table 2: Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å²).

Atom	x	y	z	$U_{\text{iso}}^*/U_{\text{eq}}$
C1	0.3890(3)	0.07595(17)	0.33409(14)	0.0516(8)
C2	0.2807(3)	0.16753(16)	0.37830(15)	0.0533(8)
C3	0.3989(3)	0.15107(17)	0.34998(15)	0.0576(9)
H3	0.469334	0.184128	0.343358	0.069*
C4	0.4836(3)	0.02830(16)	0.30237(14)	0.0505(8)
C5	0.6183(3)	0.03274(17)	0.31636(15)	0.0603(9)
H5	0.646981	0.066288	0.345563	0.072*
C6	0.7099(3)	−0.01036(17)	0.28876(14)	0.0564(8)
H6	0.799750	−0.006717	0.299160	0.068*
C7	0.6675(4)	−0.05933(18)	0.24531(15)	0.0589(9)
C8	0.5356(4)	−0.0643(2)	0.22852(15)	0.0673(10)
H8	0.508679	−0.096643	0.198204	0.081*
C9	0.4436(4)	−0.02083(19)	0.25713(14)	0.0626(9)
H9	0.354015	−0.024200	0.246218	0.075*
C10	0.2165(3)	−0.02487(16)	0.35582(14)	0.0538(8)
C11	0.2939(4)	−0.08255(17)	0.37802(15)	0.0640(9)
H11	0.381462	−0.073152	0.390111	0.077*
C12	0.2412(5)	−0.15462(19)	0.38234(18)	0.0784(12)
H12	0.293765	−0.194014	0.397436	0.094*
C13	0.1129(5)	−0.1692(2)	0.36478(18)	0.0812(12)
H13	0.077768	−0.218024	0.367998	0.097*
C14	0.0370(5)	−0.1110(2)	0.3424(2)	0.0926(14)
H14	−0.050415	−0.120629	0.330133	0.111*
C15	0.0875(4)	−0.03850(19)	0.33775(19)	0.0822(12)
H15	0.034962	0.000806	0.322538	0.099*
C16	0.2424(3)	0.24025(15)	0.40315(14)	0.0495(8)
C17	0.2760(3)	0.35460(16)	0.43067(14)	0.0503(8)
C18	0.3036(3)	0.49227(15)	0.44615(13)	0.0490(8)
C19	0.1756(3)	0.50888(17)	0.46167(15)	0.0580(9)
H19	0.114822	0.469972	0.468144	0.070*
C20	0.1384(4)	0.58543(18)	0.46756(14)	0.0639(9)
H20	0.051930	0.597136	0.477916	0.077*
C21	0.2266(4)	0.64335(18)	0.45840(15)	0.0634(10)
H21	0.200325	0.693980	0.461928	0.076*
C22	0.3542(4)	0.62560(17)	0.44396(15)	0.0653(10)
H22	0.415008	0.664674	0.438103	0.078*
C23	0.3941(4)	0.55106(17)	0.43797(14)	0.0603(9)
H23	0.481363	0.539981	0.428466	0.072*
C24	0.8949(3)	0.56743(16)	0.33028(13)	0.0498(8)
C25	0.7852(3)	0.47294(15)	0.37025(13)	0.0467(7)
C26	0.9011(3)	0.49075(16)	0.34127(14)	0.0547(8)
H26	0.968906	0.457402	0.331405	0.066*
C27	0.9924(3)	0.61734(15)	0.30187(13)	0.0507(8)
C28	1.1260(3)	0.60727(16)	0.31558(14)	0.0545(8)
H28	1.151888	0.569497	0.342073	0.065*
C29	1.2208(4)	0.65193(18)	0.29083(14)	0.0606(9)
H29	1.310318	0.644402	0.300424	0.073*
C30	1.1833(4)	0.70797(18)	0.25173(14)	0.0572(9)
C31	1.0515(4)	0.71792(19)	0.23610(15)	0.0686(10)
H31	1.026625	0.754689	0.208604	0.082*
C32	0.9560(4)	0.67289(18)	0.26153(15)	0.0626(9)
H32	0.866609	0.679994	0.251428	0.075*
C33	0.7327(3)	0.66869(16)	0.36177(14)	0.0538(8)
C34	0.7923(4)	0.70961(19)	0.40582(18)	0.0785(12)
H34	0.860665	0.688312	0.428654	0.094*
C35	0.7496(5)	0.7833(2)	0.4160(2)	0.1021(16)
H35	0.789406	0.812020	0.445878	0.123*

Table 2 (continued)

Atom	x	y	z	$U_{\text{iso}}^*/U_{\text{eq}}$
C36	0.6488(5)	0.8138(2)	0.3822(2)	0.0916(14)
H36	0.620941	0.863560	0.388822	0.110*
C37	0.5894(5)	0.7721(2)	0.3392(2)	0.0909(14)
H37	0.520318	0.793112	0.316618	0.109*
C38	0.6310(4)	0.6986(2)	0.32887(18)	0.0773(11)
H38	0.589699	0.669661	0.299537	0.093*
C39	0.7431(3)	0.39879(15)	0.39055(13)	0.0464(7)
C40	0.7719(3)	0.28299(14)	0.41504(13)	0.0432(7)
C41	0.7971(3)	0.14847(15)	0.44222(13)	0.0469(7)
C42	0.6676(4)	0.13631(17)	0.45812(15)	0.0613(9)
H42	0.607118	0.176465	0.457657	0.074*
C43	0.6283(4)	0.06473(19)	0.47464(17)	0.0757(11)
H43	0.540876	0.056686	0.485467	0.091*
C44	0.7171(4)	0.00425(19)	0.47540(17)	0.0766(11)
H44	0.689683	−0.044051	0.486847	0.092*
C45	0.8442(4)	0.01608(19)	0.45932(18)	0.0752(11)
H45	0.904277	−0.024277	0.459469	0.090*
C46	0.8848(4)	0.08827(17)	0.44264(16)	0.0658(10)
H46	0.972141	0.096049	0.431630	0.079*
N1	0.2686(3)	0.05133(13)	0.35342(11)	0.0522(7)
N2	0.2005(3)	0.10730(13)	0.38100(12)	0.0570(7)
N3	0.1313(3)	0.26436(13)	0.42108(13)	0.0614(8)
N4	0.1515(3)	0.34066(13)	0.44056(13)	0.0591(7)
N5	0.3508(3)	0.41697(13)	0.43757(12)	0.0588(7)
H5A	0.435680	0.410948	0.436741	0.071*
N6	0.7773(3)	0.59160(13)	0.35255(11)	0.0523(7)
N7	0.7085(3)	0.53417(13)	0.37771(12)	0.0526(7)
N8	0.6283(3)	0.37335(12)	0.40348(11)	0.0492(6)
N9	0.6462(3)	0.29614(12)	0.42000(11)	0.0501(6)
N10	0.8453(3)	0.22012(12)	0.42502(11)	0.0518(7)
H10	0.929649	0.224014	0.420462	0.062*
O1	0.3407(2)	0.29346(10)	0.40777(10)	0.0539(6)
O2	0.84051(19)	0.34453(10)	0.39614(9)	0.0472(5)
Cl1	0.78374(11)	−0.11647(6)	0.21089(5)	0.0868(4)
Cl2	1.30314(11)	0.76686(6)	0.22326(4)	0.0885(4)

Source of material

The title compound was synthesized from treatment of 2-(5-(4-chlorophenyl)-1-phenyl-1H-pyrazole-3-carbonyl)-N-phenylhydrazinecarbothioamide with anhydrous sodium acetate in boiling ethanol for 5 h. The solid obtained on cooling the reaction mixture was filtered, washed with ethanol, dried and crystallized from dimethylformamide to give colorless crystals (63%) of the title compound, Mp. 238–240 °C.

Experimental details

H atoms were positioned geometrically and refined using a riding model. $U_{\text{iso}}(\text{H})$ for aromatic and N–H hydrogens were set to 1.2 times U_{eq} for the atoms they are bonded to. Aromatic C–H bonds were fixed at 0.93 Å and N–H at 0.86 Å. The weakly diffracting crystal yielded a $wR2$ factor slightly larger than 20%. Nevertheless the data weren't cut, as the strongest of them may provide some information.

Comment

Heterocycles containing the 1,3,4-oxadiazol-2-amine moiety show different biological activities and act as anticancer and antiproliferative agents [5–8]. Also, the pyrazole ring system is the core of a number of drugs such as celecoxib, fezolamide and difenamisole [9–11].

The asymmetric unit comprises two independent molecules (see the figure). The molecule consists of five rings: phenyl (R1), oxadiazolyl (R2), pyrazolyl (R3), chlorophenyl (R4) and a second phenyl (R5) ring linked to R3. The twist angles between the planes of pairs of linked rings R1–R2, R2–R3, R3–R4, R3–R5 are 17.54(11), 11.94(17), 43.54(12) and 52.49(10)° respectively for the first molecule (C1–C23) and 6.81(12), 18.80(13), 43.10(11) and 78.44(11)° respectively for the second molecule (C24–C46). Weak intramolecular contacts of C–H...N type involving phenyl and oxadiazolyl rings occur. R₂²(9) rings due to N–H...N and C–H...N interactions between neighbouring molecules lead to the formation of ribbons parallel to [100].

Acknowledgements: Mohammad Hayal Alotaibi thanks King Abdulaziz City for Science and Technology (KACST), Saudi Arabia for financial support (award No. 020-0180).

References

1. Rigaku Oxford Diffraction: CrysAlis^{PRO}. Rigaku Oxford Diffraction, Yarnton, England (2015).
2. Sheldrick, G. M.: A short history of SHELX. *Acta Crystallogr. A* **64** (2008) 112–122.
3. Sheldrick, G. M.: Crystal structure refinement with SHELXL. *Acta Crystallogr. C* **71** (2015) 3–8.
4. Farrugia, L. J.: WinGX and ORTEP for Windows: an update. *J. Appl. Crystallogr.* **45** (2012) 849–854.
5. Ahsan, M. J.; Sharma, J.; Singh, M.; Jadav, S. S.; Yasmin, S.: Synthesis and anticancer activity of *N*-aryl-5-substituted-1,3,4-oxadiazol-2-amine analogues. *Biomed. Res. Int.* **2014** (2014) 81498.
6. Kumar, D.; Patel, G.; Chavers, A. K.; Chang, K. H.; Shah, K.: Synthesis of novel 1,2,4-oxadiazoles and analogues as potential anticancer agents. *Eur. J. Med. Chem.* **46** (2011) 3085–3092.
7. Gonda, T.; Bérdi, P.; Zupkó, I.; Fülöp, F.; Szakonyi, Z.: Stereoselective synthesis, synthetic and pharmacological application of monoterpene-based 1,2,4- and 1,3,4-oxadiazoles. *Int. J. Mol. Sci.* **19** (2017) 81.
8. Kumar, D.; Patel, G.; Johnson, E. O.; Shah, K.: Synthesis and anticancer activities of novel 3,5-disubstituted-1,2,4-oxadiazoles. *Bioorg. Med. Chem. Lett.* **19** (2009) 2739–2741.
9. Karrouchi, K.; Radi, S.; Ramli, Y.; Taoufik, J.; Mabkhot, Y. N.; Al-Aizari, F. A.; Ansar, M.: Synthesis and pharmacological activities of pyrazole derivatives: a review. *Molecules* **23** (2018) 134.
10. Khan, M. F.; Alam, M. M.; Verma, G.; Akhtar, W.; Akhter, M.; Shaquiquzzaman, M.: The therapeutic voyage of pyrazole and its analogs: a review. *Eur. J. Med. Chem.* **120** (2016) 170–201.
11. Ganguly, S.; Jacob, S. K.: Therapeutic outlook of pyrazole analogs: a mini review. *Mini-Rev. Med. Chem.* **17** (2017) 959–983.